Drugs / KTX2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07103018 | Nov 2025 → Sep 2027 expected | prostate carcinoma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KTX2001 | “Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer” NCT07103018 ↗ |
| Action | Inhibit | “KTX2001 (an NSD2 Inhibitor)” NCT07103018 ↗ |
| Route | Oral | “KTX-2001 orally” NCT07103018 ↗ |
| Target | NSD2 | “KTX2001 (an NSD2 Inhibitor)” NCT07103018 ↗ |